Kymera Therapeutics (KYMR) Income towards Parent Company: 2019-2025
Historic Income towards Parent Company for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$92.6 million.
- Kymera Therapeutics' Income towards Parent Company fell 28.31% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 65.94%. This contributed to the annual value of -$261.9 million for FY2024, which is 58.02% down from last year.
- Per Kymera Therapeutics' latest filing, its Income towards Parent Company stood at -$92.6 million for Q3 2025, which was down 9.39% from -$84.7 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Income towards Parent Company ranged from a high of -$13.2 million in Q1 2021 and a low of -$92.6 million during Q3 2025.
- For the 3-year period, Kymera Therapeutics' Income towards Parent Company averaged around -$61.8 million, with its median value being -$57.9 million (2024).
- Per our database at Business Quant, Kymera Therapeutics' Income towards Parent Company skyrocketed by 49.95% in 2023 and then plummeted by 317.34% in 2024.
- Kymera Therapeutics' Income towards Parent Company (Quarterly) stood at -$34.0 million in 2021, then dropped by 13.64% to -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then slumped by 317.34% to -$80.8 million in 2024, then dropped by 28.31% to -$92.6 million in 2025.
- Its Income towards Parent Company stands at -$92.6 million for Q3 2025, versus -$84.7 million for Q2 2025 and -$74.5 million for Q1 2025.